Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Passage Bio (NASDAQ:PASG) Q3 Loss of USD 1.47 Per Share Matches Estimate as Cash Falls to USD 20.2 Million

Research and development expenses were USD 1,497 thousand against USD 4,307 thousand, and general and administrative expenses were USD 3,444 thousand against USD 4,348 thousand. Weighted average shares were 3,217,810 against 3,178,710.

Nitish Kishor | 12 November 2026

Palladyne AI (NASDAQ:PDYN) Posts Record USD 8.56 Million Q3 Revenue, Ahead of Estimates

Compared with the second quarter, components revenue grew 26%, helped by the first deliveries of the company's BRAIN FC1 flight computers, while revenue from government contracts increased 135%.

Nitish Kishor | 12 November 2026

Where Does PepGen (NASDAQ:PEPG) Stand After Q3 Results and a Partial Clinical Hold?

General and administrative expenses rose USD 0.7 million to USD 5.9 million in the quarter. Cash, cash equivalents and marketable securities totaled USD 104.8 million at September 30, held in a checking account and U.S. treasury-backedMoney Marketfunds. The accumulated deficit was USD 416.1 million.

Nitish Kishor | 12 November 2026

PetMed Express (NASDAQ:PETS) Fiscal Q2 Net Sales Fall 19.4% to USD 35.8 Million With Going Concern Disclosure

Net sales fell about 19.4%, or USD 8.6 million, from the prior-year quarter. Net loss was USD 6.4 million against USD 8.5 million, and USD 12.6 million for the six months against USD 42.7 million.

Nitish Kishor | 12 November 2026

Protalix BioTherapeutics (NYSE American:PLX) Q3 Earnings Beat: EPS of USD 0.05 and Revenue of USD 21.9 Million

For the first nine months, total revenue was USD 75.6 million against USD 43.6 million in the prior-year period. Revenue from selling goods for the nine months was USD 49.1 million, up USD 6.0 million. The filing attributes the rise in goods revenue primarily …

Nitish Kishor | 12 November 2026

PMV Pharmaceuticals (NASDAQ:PMVP) Q3 Loss of USD 0.52 Per Share Widens Ahead of Planned NDA Filing

The quarter included expenses linked to the August 2026 public offering, including offering costs allocated to liability-classified common stock warrants that were expensed on issuance. There were no comparable amounts in the third quarter of 2025.

Nitish Kishor | 12 November 2026

Precipio (NASDAQ:PRPO) Q3 Revenue Is USD 7.3 Million as Management Sets Annualized Run Rate Targets for 2027

The filing states that patient diagnostic service revenue increased USD 0.3 million from the same period in 2025, and product revenue increased USD 0.3 million primarily on revenue from new product related projects.Gross Profitincreased USD 0.4 million. Management said its 2025 results were relatively …

Nitish Kishor | 12 November 2026

Pixelworks (NASDAQ:PXLW) Posts Q3 Revenue of USD 378,000 and a USD 0.46 Loss Per Share, Missing the Per Share Estimate

Management said revenue increased sequentially and by more than 50% year over year, and that nine month revenue was USD 888,000. For context, it said full year 2025 revenue associated with its motion grading technology was approximately USD 690,000.

Nitish Kishor | 12 November 2026

PolyPid (NASDAQ:PYPD) Reports Q3 Loss of USD 0.24 Per Share as FDA Goal Date for D-PLEX100 Nears

For the first nine months, net loss was USD 21.3 million, or USD 0.94 per share, against USD 25.7 million, or USD 1.72 per share.

Nitish Kishor | 12 November 2026

What D-Wave Quantum (NASDAQ:QBTS) Reported on Revenue, Bookings and Spending in Q3

The company recognized revenue from more than 100 customers. Commercial enterprises accounted for 52% of revenue, up from 31% in the third quarter of 2025.

Nitish Kishor | 12 November 2026
Support

Hi! How can we help you today?

Loading…